Teva launches transdermal fentanyl in the US
This article was originally published in Scrip
Teva Pharmaceutical Industrieshas received US FDA approval and started shipping its fentanyl transdermal patches, in 25, 50, 75 and 100 μg/hour doses, AB-rated generic versions of Ortho-McNeil's (J&J) Duragesic. Generic fentanyl patches are already available in the US from other companies, including Mylan, Watson, Lavipharm and Actavis. Earlier this year, lots of Watson's and Actavis's versions were separately adversely affected by manufacturing issues. Teva's version is manufactured by Aveva Drug Delivery Systems, a division of Nitto Denko, which Teva describes as one of the world's largest manufacturers of, and pioneer in, drug-in-adhesive transdermal patch technology.
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.
Top-line results from a Phase IIb study of Theravance’s potential gut-selective JAK inhibitor izencitinib have not matched expectations, and results from a similar early-stage study in Crohn’s disease with the Janssen-partnered candidate are now awaited at the end of the year or in early 2022.